BR112014028561A2 - composição farmacêutica compreendendo (1r,4r )-6'-fluoro-n, n-dimetil-4-fenil-4', 9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina e paracetamol ou propacetamol - Google Patents

composição farmacêutica compreendendo (1r,4r )-6'-fluoro-n, n-dimetil-4-fenil-4', 9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina e paracetamol ou propacetamol

Info

Publication number
BR112014028561A2
BR112014028561A2 BR112014028561A BR112014028561A BR112014028561A2 BR 112014028561 A2 BR112014028561 A2 BR 112014028561A2 BR 112014028561 A BR112014028561 A BR 112014028561A BR 112014028561 A BR112014028561 A BR 112014028561A BR 112014028561 A2 BR112014028561 A2 BR 112014028561A2
Authority
BR
Brazil
Prior art keywords
propacetamol
acetaminophen
pyran
spiro
indole
Prior art date
Application number
BR112014028561A
Other languages
English (en)
Portuguese (pt)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of BR112014028561A2 publication Critical patent/BR112014028561A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112014028561A 2012-05-18 2013-05-16 composição farmacêutica compreendendo (1r,4r )-6'-fluoro-n, n-dimetil-4-fenil-4', 9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina e paracetamol ou propacetamol BR112014028561A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003897 2012-05-18
PCT/EP2013/001468 WO2013170969A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol

Publications (1)

Publication Number Publication Date
BR112014028561A2 true BR112014028561A2 (pt) 2017-07-25

Family

ID=48468208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028561A BR112014028561A2 (pt) 2012-05-18 2013-05-16 composição farmacêutica compreendendo (1r,4r )-6'-fluoro-n, n-dimetil-4-fenil-4', 9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina e paracetamol ou propacetamol

Country Status (22)

Country Link
US (3) US20130310435A1 (cg-RX-API-DMAC7.html)
EP (1) EP2849740B1 (cg-RX-API-DMAC7.html)
JP (1) JP6116676B2 (cg-RX-API-DMAC7.html)
CN (2) CN108524498A (cg-RX-API-DMAC7.html)
AU (1) AU2013262075B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014028561A2 (cg-RX-API-DMAC7.html)
CA (1) CA2873644A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119610T1 (cg-RX-API-DMAC7.html)
DK (1) DK2849740T3 (cg-RX-API-DMAC7.html)
EA (1) EA026949B1 (cg-RX-API-DMAC7.html)
ES (1) ES2650441T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171438T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034676T2 (cg-RX-API-DMAC7.html)
IL (1) IL235651B (cg-RX-API-DMAC7.html)
LT (1) LT2849740T (cg-RX-API-DMAC7.html)
MX (1) MX352596B (cg-RX-API-DMAC7.html)
NO (1) NO2849740T3 (cg-RX-API-DMAC7.html)
PL (1) PL2849740T3 (cg-RX-API-DMAC7.html)
PT (1) PT2849740T (cg-RX-API-DMAC7.html)
RS (1) RS56617B1 (cg-RX-API-DMAC7.html)
SI (1) SI2849740T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013170969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
MX2018010367A (es) 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2026161433A1 (en) * 2025-01-21 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for alleviating pain
WO2026161842A1 (en) * 2025-01-27 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for treating pain

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
IE55189B1 (en) 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ES2098264T3 (es) 1989-05-22 1997-05-01 Biochemical Veterinary Res Sales metalicas divalentes de indometacina.
AU662160B2 (en) 1991-07-04 1995-08-24 Taisho Pharmaceutical Co., Ltd. Analgesic
JPH05221857A (ja) * 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
EP0702681A1 (en) 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin antagonists
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EA004032B1 (ru) 1998-09-10 2003-12-25 Нюкомед Данмарк А/С Фармацевтические композиции лекарственных веществ с быстрым высвобождением
ES2194536T3 (es) 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
EP1470126A1 (en) 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
ATE359827T1 (de) 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2006257274A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists
CN102675136B (zh) 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101431990B (zh) * 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
CN101147735A (zh) * 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
US20100279984A1 (en) 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
EP2331087A1 (en) * 2008-09-05 2011-06-15 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol
WO2010025931A2 (en) 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
CA2735139A1 (en) 2008-09-05 2010-03-11 Petra Bloms-Funke Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
EP3459533A1 (en) * 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
AR082559A1 (es) * 2010-08-04 2012-12-19 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6’-fluoro-(n-metil- o n,n-dimetil)-4’-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina
RU2589831C2 (ru) * 2010-08-04 2016-07-10 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

Also Published As

Publication number Publication date
EA026949B1 (ru) 2017-06-30
US20190350884A1 (en) 2019-11-21
RS56617B1 (sr) 2018-02-28
HRP20171438T1 (hr) 2017-11-03
MX352596B (es) 2017-11-30
JP2015516449A (ja) 2015-06-11
AU2013262075B2 (en) 2017-10-26
WO2013170969A1 (en) 2013-11-21
PT2849740T (pt) 2017-12-13
EP2849740B1 (en) 2017-09-13
CY1119610T1 (el) 2018-04-04
MX2014012723A (es) 2015-01-15
ES2650441T3 (es) 2018-01-18
DK2849740T3 (da) 2017-11-20
JP6116676B2 (ja) 2017-04-19
US20180092867A1 (en) 2018-04-05
HK1204940A1 (en) 2015-12-11
US11311504B2 (en) 2022-04-26
HUE034676T2 (hu) 2018-02-28
CN104302282A (zh) 2015-01-21
LT2849740T (lt) 2017-12-27
PL2849740T3 (pl) 2018-03-30
EA201401272A1 (ru) 2015-05-29
SI2849740T1 (en) 2018-01-31
NO2849740T3 (cg-RX-API-DMAC7.html) 2018-02-10
IL235651B (en) 2018-08-30
AU2013262075A1 (en) 2015-01-22
IL235651A0 (en) 2015-01-29
CA2873644A1 (en) 2013-11-21
EP2849740A1 (en) 2015-03-25
US20130310435A1 (en) 2013-11-21
CN108524498A (zh) 2018-09-14

Similar Documents

Publication Publication Date Title
PT2849745T (pt) Composição farmacêutica compreendendo (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina e ibuprofeno
IL235658A (en) Pharmaceutical Composition Containing (1r, 4r) - 6 '- Fluoro - n, n - Dimethyl - 4 - Phenyl - 4', 9 '- Dihydro - 3'h - Spiro [Cyclohexane - 1, 1' - Pirano [3, 4 , b] indole] - 4 - amine and gabapentinoid
IL235654A0 (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] Indole] – 4 – amine and anticonvulsant drug
IL235651A0 (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] Indole] - 4 - amine and paracetamol or propacetamol
IL235657A0 (en) Pharmacy device containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and antidepressants
IL235652B (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro -3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and oxicam
IL235653B (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and a non-steroidal anti-rheumatic drug
PL2852386T3 (pl) Kompozycja farmaceutyczna zawierająca (1r,4r)-6’-fluoro-n,n-dimetylo-4-fenylo-4’,9’-dihydro-3’h-spiro[cykloheksano-1,1’-pirano-[3,4,b]indolo]-4-aminę oraz kwas acetylosalicylowy
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.